TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TXMD” or the “Company”) an innovative, leading women's healthcare company, announced today the closing of the divestiture of vitaCare Prescription Services to GoodRx (NASDAQ: GDRX), in a cash transaction valued at $150 million, subject to a working capital adjustment. The Company previously announced the signing of a definitive agreement on March 6, 2022. TherapeuticsMD remains eligible to receive an additional $7 million

TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

Leju Holdings Ltd.

Secoo Hld

China SXT Pharmaceuticals Inc

Penny Stocks Under $1 To Watch This Week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 Explosive Stocks Under $1 To Watch Now

TherapeuticsMD had a rough 2021, and the share price shows it. The company battled the COVID-19 headwinds and has struggled to expand ANNOVERA's manufacturing.

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd On Q4 2021 Results - Earnings Call Transcript

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50% and 37.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD (TXMD) Reports Q4 Loss, Lags Revenue Estimates

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the fourth quarter ended December 31, 2021. “We spent the past three months executing on four key priorities set forth last quarter, and today we announced that we have accomplished two of them. With the definitive agreement to fully divest our vitaCare business unit, TXMD will emerge as a more focused company a

TherapeuticsMD Announces Fourth Quarter 2021 Financial Results

TherapeuticsMD Inc (NASDAQ: TXMD) is trading higher Monday after the company announced it would sell its prescription services business, vitaCare, to GoodRx Holdings Inc (NASDAQ: GDRX). Under terms of the agreement, TherapeuticsMD will receive $150 million in cash.

Why TherapeuticsMD Shares Are Soaring Today

Imperial Petroleum

VEON

Here's what you need to know about trading penny stocks on March 7th The post Trading Penny Stocks? Top Stock Market News for March 7th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for March 7th, 2022

TherapeuticsMD Inc (NASDAQ: TXMD) has agreed to divest its VitaCare Prescription Services business to GoodRx Holdings Inc (NASDAQ: GDRX) for $150 million. VitaCare is a consumer-focused digital healthcare platform.

TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it has entered into a definitive agreement to divest its vitaCare Prescription Services (vitaCare) business to GoodRx (Nasdaq: GDRX), a consumer-focused digital healthcare platform. VitaCare is a technology and services platform that helps patients navigate key access and adherence barriers for brand medications. Under the term

TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its fourth quarter 2021 financial results on Thursday, March 10, 2022, before the opening of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date: Thursday, March 10, 2022 Time: 8:30 a.m. ET Telephone Access

TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022

Farmmi

Oragenics

Looking for penny stocks to buy under $1? Check these three out for your watchlist The post 3 Penny Stocks To Watch Under $1 That Are Moving Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Watch Under $1 That Are Moving Right Now

TherapeuticsMD Inc (NASDAQ: TXMD) is trading sharply higher after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause. In a regulatory filing, TherapeuticsMD said that on December 28, the agency cleared its supplemental marketing application for Bijuva, seeking approval for the capsule at the 0.5 mg/100 mg dose level.

FDA Approves TherapeuticsMD's Low Dose Bijuva

TherapeuticsMD Inc (NASDAQ: TXMD) said that the FDA could not approve revisions to certain manufacturing testing limits for Annovera through the supplemental marketing application previously submitted by the Company.  The supplemental application requested minor revisions to the in vitro release testing specification for Annovera to allow for normal commercial manufacturing variation.

TherapeuticsMD's Birth Control Med Receives FDA Response Letter To Revise Manufacturing Testing Limits

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) (“TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced that the FDA determined that it could not approve revisions to certain manufacturing testing limits for ANNOVERA through the sNDA previously submitted by the Company. In its complete response letter, the FDA provided recommendations and requested additional information that could support approval of revisions to certain manufacturing

U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®

The stock price of TherapeuticsMD, Inc. (NASDAQ: TXMD) increased by over 3% pre-market today. This is why it happened.

TherapeuticsMD Stock (TXMD): Why The Price Increased Today

Amneal Pharmaceuticals

TherapeuticsMD Inc (NASDAQ: TXMD) has settled the previously disclosed U.S. patent litigation for Bijuva with Amneal Pharmaceuticals Inc (NYSE: AMRX). Bijuva is a prescription medicine used to treat vasomotor symptoms (hot flashes) related to menopause.

TherapeuticsMD, Amneal Settle US Patent Litigation For Bijuva

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of New York LLC (collectively “Amneal”). As part of the settlement, TherapeuticsMD granted to Amneal a license to commercialize Amneal's generic version of BIJUVA (1 mg estradiol and 100 mg p

TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date

TherapeuticsMD, Inc. (TXMD) CEO Rob Finizio on Q3 2021 Earnings Conference Call - Earnings Call Transcript

TherapeuticsMD (NASDAQ:TXMD) reported its Q3 earnings results on Thursday, November 11, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Recap: TherapeuticsMD Q3 Earnings

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the third quarter ended September 30, 2021. In addition, today the Company announced a significant cost savings initiative designed to reduce its annual costs in 2022 by at least $40 million. This figure does not include savings from, or the costs associated with, the divestiture of vitaCare, which are estimated

TherapeuticsMD Announces Third Quarter 2021 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (TXMD or the Company), an innovative, leading women's healthcare company, today announced key leadership changes, including the appointment of Hugh O'Dowd, the Company's current President, as the Company's Chief Executive Officer and member of the board of directors. Mr. O'Dowd will succeed Robert G. Finizio, the Company's Co-founder and current Chief Executive Officer, effective on or before December 31, 2021. Mr. Finizio w

TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer

TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Senmiao Technology

BIMI International Medical

Meten Holding Group Ltd.

Regulus Therapeutics

Are these Webull penny stocks to buy or avoid right now? The post 5 Penny Stocks To Buy For Under $1 On Webull Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy For Under $1 On Webull Right Now

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced that it will report its third quarter 2021 financial results on Thursday, November 11, 2021, before the opening of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date: Thursday, November 11, 2021 Time: 8:30 a.m. ET Telephone Ac

News for TherapeuticsMD Stock (TXMD)